Cancer Survivor Cardiomyopathy Detection

NCT ID: NCT05201014

Last Updated: 2025-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

112 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-03

Study Completion Date

2026-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to define the diagnostic performance and optimal cutoffs of AI-ECG and NT-pro-BNP for the detection of left ventricular dysfunction \[LVD, defined as a left ventricular ejection fraction (LVEF) \<50%\] in cancer patients at 1 year after completion of anthracycline-based chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 year follow-up

patients who were treated in the year before and are now returning for their 1-year follow-up.

NT-pro-BNP

Intervention Type DIAGNOSTIC_TEST

Blood draw

Electrocardiogram

Intervention Type DIAGNOSTIC_TEST

electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart

Echocardiogram

Intervention Type DIAGNOSTIC_TEST

medical imaging of the heart

Prior to anthracycline-based therapy

patients presenting before the start of anthracycline-based therapy, then to be followed thereafter for 1 year and thereby contributing to the pool of patients with 1-year post-anthracycline assessment.

NT-pro-BNP

Intervention Type DIAGNOSTIC_TEST

Blood draw

Electrocardiogram

Intervention Type DIAGNOSTIC_TEST

electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart

Echocardiogram

Intervention Type DIAGNOSTIC_TEST

medical imaging of the heart

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NT-pro-BNP

Blood draw

Intervention Type DIAGNOSTIC_TEST

Electrocardiogram

electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart

Intervention Type DIAGNOSTIC_TEST

Echocardiogram

medical imaging of the heart

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Blood Biomarker

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years of age prior to enrollment and anthracycline start date
* Diagnosis of breast cancer, lymphoma, or sarcoma with either planned or at 1 year after completion of anthracycline therapy, including patients from 6-12 months and greater than 1 year post-anthracycline exposure.
* Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same

Exclusion Criteria

* LVEF \<50% or prior confirmed history of cardiomyopathy, heart failure, left bundle branch block, or paced rhythm
* Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same.
* Individuals with pacemakers, defibrillators, or other implanted electronic devices
* Inability/unwillingness of individual to give written informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Florida Heart Research Institute

OTHER

Sponsor Role collaborator

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Joerg Herrmann, MD

Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joerg Herrmann, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2022-05920

Identifier Type: REGISTRY

Identifier Source: secondary_id

21-006790

Identifier Type: OTHER

Identifier Source: secondary_id

CASCADE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The SMARTER Cardiomyopathy Study
NCT05750147 RECRUITING